Can we afford it?
The cost of new drugs is a major issue in the NHS; some of the recently introduced therapeutic agents are eye-wateringly expensive, and this can create challenging situations for those who struggle to do their best for individual patients, while their managers try to keep some sort of overall budgetary control. Dermatology is not immune to this, with important but expensive new treatments for psoriasis, melanoma and basal cell carcinoma.
Dermatology in practice 2015; 21(3): 71–71
To continue reading this article, please sign in or register.